One Shot, Months of Control: China's 'Hypertension Vaccine' Heads Into Phase Two
17 hours ago
A Wuhan biotech firm's 'hypertension vaccine' has cleared its first-in-human trial and will move into Phase II, promising months of blood-pressure control from a few injections a year — a prospect aimed at China's 330 million hypertension patients.








